European guidelines for the systemic treatment of moderate-to-severe psoriasis vulgaris suggest considering anti-TNFα agents, ustekinumab, IL-17, and IL-23 inhibitors for patients with cancer, with individualized assessments considering patient preferences and remission durations. The gene discussed is IL23A; the disease is psoriasis vulgaris.